

**SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE
THERAPEUTIC STUDIES ONLY (TXCA=Y)
32% of Calendar Year is Past**

<u>COMMITTEE</u>	<u>Base Accrual 2010</u>	<u>2018 Accrual to date</u>	<u>Percentage of Base Accrual</u>	<u>Projected 2018 Accrual</u>	<u>Projected Increase <Decrease> from Base</u>	<u>Accrual Last 12 Months</u>	<u>12 Month Increase <Decrease> from Base</u>
BREAST	1558	295	19%	928	-629	1186	-372
ERLYTX	76	240	316%	755	679	484	408
GI	476	57	12%	179	-296	225	-251
GU	450	80	18%	251	-198	328	-122
GYN	57	0	0%	0	-57	0	-57
LEUK	150	23	15%	72	-77	52	-98
LUNG	524	100	19%	314	-209	338	-186
LYMPH	172	5	3%	15	-156	9	-163
MELAN	55	30	55%	94	39	485	430
MMYEL	147	41	28%	129	-17	91	-56
OTHER	0	14		44	44	40	40
SXQOL	0	1		3	3	1	1
Total	3665	886		2784	-874	3239	-426

**SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE
NON-THERAPEUTIC STUDIES ONLY (TXCA=N)
32% of Calendar Year is Past**

<u>COMMITTEE</u>	<u>Base Accrual 2010</u>	<u>2018 Accrual to date</u>	<u>Percentage of Base Accrual</u>	<u>Projected 2018 Accrual</u>	<u>Projected Increase <Decrease> from Base</u>	<u>Accrual Last 12 Months</u>	<u>12 Month Increase <Decrease> from Base</u>
BREAST	37	76	205%	239	202	112	75
CCD	0	527		1658	1658	1543	1543
GU	0	0		0	0	0	0
LEUK	69	5	7%	15	-53	7	-62
LUNG	43	215	500%	676	633	576	533
LYMPH	53	1	2%	3	-49	1	-52
MMYEL	92	0	0%	0	-92	0	-92
OTHER	0	0		0	0	4	4
PREV	0	16		50	50	95	95
SURV	0	37		116	116	101	101
<u>SXQOL</u>	<u>878</u>	<u>3</u>	<u>0%</u>	<u>9</u>	<u>-868</u>	<u>6</u>	<u>-872</u>
Total	1172	880		2766	1597	2445	1273

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE
ALL ACCRUAL REGISTRATIONS
32% of Calendar Year is Past

<u>COMMITTEE</u>	<u>Base Accrual 2010</u>	<u>2018 Accrual to date</u>	<u>Percentage of Base Accrual</u>	<u>Projected 2018 Accrual</u>	<u>Projected Increase <Decrease> from Base</u>	<u>Accrual Last 12 Months</u>	<u>12 Month Increase <Decrease> from Base</u>
BREAST	1595	371	23%	1167	-427	1298	-297
CCD	0	527		1658	1658	1543	1543
ERLYTX	76	240	316%	755	679	484	408
GI	476	57	12%	179	-296	225	-251
GU	450	80	18%	251	-198	328	-122
GYN	57	0	0%	0	-57	0	-57
LEUK	219	28	13%	88	-130	59	-160
LUNG	567	315	56%	991	424	914	347
LYMPH	225	6	3%	18	-206	10	-215
MELAN	55	30	55%	94	39	485	430
MMYEL	239	41	17%	129	-109	91	-148
OTHER	0	14		44	44	44	44
PREV	0	16		50	50	95	95
SURV	0	37		116	116	101	101
SXQOL	878	4	0%	12	-865	7	-871
Total	4837	1766		5552	722	5684	847

**SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE
THERAPEUTIC REGISTRATIONS BY SWOG INSTITUTIONS ONLY (TXCA=Y)
32% of Calendar Year is Past**

<u>COMMITTEE</u>	<u>Base Accrual 2010</u>	<u>2018 Accrual to date</u>	<u>Percentage of Base Accrual</u>	<u>Projected 2018 Accrual</u>	<u>Projected Increase <Decrease> from Base</u>	<u>Accrual Last 12 Months</u>	<u>12 Month Increase <Decrease> from Base</u>
BREAST	1012	179	18%	563	-448	604	-408
ERLYTX	76	159	209%	500	424	313	237
GI	418	36	9%	113	-304	144	-274
GU	375	58	15%	182	-192	232	-143
GYN	57	0	0%	0	-57	0	-57
LEUK	122	16	13%	50	-71	39	-83
LUNG	441	75	17%	235	-205	237	-204
LYMPH	129	4	3%	12	-116	8	-121
MELAN	55	18	33%	56	1	256	201
MMYEL	85	39	46%	122	37	89	4
OTHER	0	14		44	44	40	40
SXQOL	0	1		3	3	1	1
Total	2770	599		1880	-884	1963	-807

**SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE
NON-THERAPEUTIC STUDIES FOR SWOG INSTITUTIONS ONLY (TXCA=N)
32% of Calendar Year is Past**

<u>COMMITTEE</u>	<u>Base Accrual 2010</u>	<u>2018 Accrual to date</u>	<u>Percentage of Base Accrual</u>	<u>Projected 2018 Accrual</u>	<u>Projected Increase <Decrease> from Base</u>	<u>Accrual Last 12 Months</u>	<u>12 Month Increase <Decrease> from Base</u>
BREAST	10	73	730%	229	219	109	99
CCD	0	379		1192	1192	1137	1137
GU	0	0		0	0	0	0
LEUK	69	5	7%	15	-53	7	-62
LUNG	30	146	487%	459	429	402	372
LYMPH	53	1	2%	3	-49	1	-52
MMYEL	92	0	0%	0	-92	0	-92
OTHER	0	0		0	0	4	4
PREV	0	8		25	25	76	76
SURV	0	25		78	78	63	63
<u>SXQOL</u>	<u>740</u>	<u>3</u>	<u>0%</u>	<u>9</u>	<u>-730</u>	<u>6</u>	<u>-734</u>
Total	994	640		2010	1019	1805	811

**SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE
ALL ACCRUAL REGISTRATIONS BY SWOG INSTITUTIONS ONLY
32% of Calendar Year is Past**

<u>COMMITTEE</u>	<u>Base Accrual 2010</u>	<u>2018 Accrual to date</u>	<u>Percentage of Base Accrual</u>	<u>Projected 2018 Accrual</u>	<u>Projected Increase <Decrease> from Base</u>	<u>Accrual Last 12 Months</u>	<u>12 Month Increase <Decrease> from Base</u>
BREAST	1022	252	25%	792	-229	713	-309
CCD	0	379		1192	1192	1137	1137
ERLYTX	76	159	209%	500	424	313	237
GI	418	36	9%	113	-304	144	-274
GU	375	58	15%	182	-192	232	-143
GYN	57	0	0%	0	-57	0	-57
LEUK	191	21	11%	66	-124	46	-145
LUNG	471	221	47%	695	224	639	168
LYMPH	182	5	3%	15	-166	9	-173
MELAN	55	18	33%	56	1	256	201
MMYEL	177	39	22%	122	-54	89	-88
OTHER	0	14		44	44	44	44
PREV	0	8		25	25	76	76
SURV	0	25		78	78	63	63
SXQOL	740	4	1%	12	-727	7	-733
Total	3764	1239		3892	135	3768	4

**SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE
ALL ACCRUAL REGISTRATIONS TO CANCER CONTROL STUDIES
32% of Calendar Year is Past**

<u>COMMITTEE</u>	<u>Base Accrual 2010</u>	<u>2018 Accrual to date</u>	<u>Percentage of Base Accrual</u>	<u>Projected 2018 Accrual</u>	<u>Projected Increase <Decrease> from Base</u>	<u>Accrual Last 12 Months</u>	<u>12 Month Increase <Decrease> from Base</u>
BREAST	65	248	382%	780	715	987	922
CCD	0	527		1658	1658	1543	1543
GI	81	14	17%	44	-36	37	-44
GU	215	51	24%	160	-54	130	-85
LEUK	0	5		15	15	7	7
LUNG	53	24	45%	75	22	93	40
LYMPH	7	1	14%	3	-3	1	-6
MELAN	0	2		6	6	390	390
MMYEL	0	41		129	129	91	91
OTHER	0	0		0	0	13	13
PREV	0	16		50	50	95	95
SURV	0	37		116	116	101	101
<u>SXQOL</u>	<u>878</u>	<u>4</u>	<u>0%</u>	<u>12</u>	<u>-865</u>	<u>7</u>	<u>-871</u>
Total	1299	970		3048	1753	3495	2196

SWOG OPEN AND TEMPORARILY CLOSED STUDIES

Comm.	Phase	Study	Stat Center	Open Date	Months Open	Total Regs	Accrual Goal	Monthly Accrual Rate	Date of Expected Closure or Temporary Closure
BREAST	II	S1416 Brst, TNBC/BRCA, Cis+/- ABT-888	SWOG	07JUL2016:00:00:00	21	244	333	13.7	Oct-2018
	II-III	NRGBR002 Brst, OMBC, II-III, SoC +/- SBRT and/or SA	NRG	24DEC2014:00:00:00		1		0.0	
	III	A011106 Breast, Neoadj, ALTERNATE study	ALLIANCE	15FEB2014:00:00:00		56		1.0	
		A011202 Breast, Nodal XRT +/- ALND	ALLIANCE			67			
		A011401 Breast, adj, Stage II/III HER2-, weight loss	ALLIANCE	29AUG2016:00:00:00		133		9.2	
		A011502 Brst, Adj, Nodal+&HER2-, Aspirin vs. Placebo	ALLIANCE	08DEC2016:00:00:00		35		2.7	
		B51 Breast, Regional Nodal XRT	NRG			25			
		B55 Brst, Adj Olaparib for BRCA,TNBC	NRG	03JUL2014:00:00:00		24		0.7	
		E2112 Brst,Adv,Exemestane+/-Entinostat	ECOG-ACR	02JAN2014:00:00:00		46		1.0	
		EA1151 Brst, Tomosynthesis Mammographic Screening	ECOG-ACRIN	06JUL2017:00:00:00		60		10.0	
		NRGBR003 Brst,Adj,TNBC,AC -> WP +/- Carbo	NRG	22JAN2015:00:00:00		51		1.2	
		S1207 Brst,Adj,Endocrine+/-Everolimus	SWOG	03SEP2013:00:00:00	55	1576	1900	30.5	Feb-2019
		S1222 Brst,Fulv. +/- Ever. +/- Anastr.	SWOG	09MAY2014:00:00:00		37	840		Feb-2015 Temp Close
		S1418 Breast, Adj, TNBC, MK-3475 (Pembrolizumab)	SWOG	15NOV2016:00:00:00	17	178	1000	16.5	May-2022
	OTHER	A221405 Breast, ET interruption, Pregnancy Outcomes	ALLIANCE	15OCT2015:00:00:00		9		0.8	
		E1Z11 Brst,Genetic Predictors of AIMSS	ECOG-ACRIN	10MAY2013:00:00:00		150		1.0	
CCD	III	A011104 Preoperative Breast MRI	ALLIANCE	21FEB2014:00:00:00		13		0.5	
		A191402C PROS, Testing Decision Aids for Minority Men	Alliance	14JUL2017:00:00:00		4		0.7	
		S1415CD TrACER CSF Standing Order Intervention for FN	SWOG	01SEP2016:00:00:00	19	1681	3960	113.2	Dec-2019
	OTHER	S1417CD Colorectal, Cost Cohort Study	SWOG	13MAY2016:00:00:00	23	232	374	18.3	Nov-2018
ERLYTX	II	A071401 Prog Meningiomas,SMO/AKT/NF2 Inhib	ALLIANCE	06AUG2015:00:00:00		5		0.0	
		S1609 Rare Tumor, Comb Nivo/Ipi	SWOG	13JAN2017:00:00:00	15	467	707	56.8	Aug-2018
	II-III	A071102 GBM, adj TMZ +/- Veliparib	ALLIANCE	19SEP2014:00:00:00		40		0.5	
		ARST1321 NonRhabdo STS,Pazopanib (PAZNTIS)	COG	16MAY2014:00:00:00		7		0.5	
	OTHER	EAY131 MATCH	ECOG-ACR	12AUG2015:00:00:00		110		1.5	
GI	II	A021501 Adeno Panc,Borderline Resect,Chemo vs ChemoRT	ALLIANCE	01DEC2016:00:00:00		14		0.7	
		EA2142 GI NEC, Adv G3, EP vs TMZ + CAP	ECOG-ACRIN	06NOV2015:00:00:00		4		0.0	
		NRGGI002 Rectal, Ph II, Sensitization using TNT	NRG	12OCT2016:00:00:00		6		0.7	
		S1613 mCRC, Adv/Met, TP vs CETIRI	SWOG	09OCT2017:00:00:00	6	1	130	0.2	> 15 Yrs
	II-III	N1048 Rectal,LocalAdv,ChemoRT+/-FOLFOX	ALLIANCE	13JAN2012:00:00:00		148		2.7	
	III	A021502 Colon, Stg III, Chemo +/- Atezol, ATOMIC	ALLIANCE	12SEP2017:00:00:00		2		0.3	
		NRGGI004 Colorectal, Stg IV, dMMR Immuno-Therapy	NRG	07NOV2017:00:00:00		1		0.2	
		R0848 Panc, Adj, Erlotinib v ChemoRT	NRG	01MAR2014:00:00:00		20		0.0	
GU	II	S1500 pRCC,Adv, Sunitinib vs MET inhib	SWOG	05APR2016:00:00:00	24	79	180	4.5	Feb-2020
		S1605 Blad, BCG-Unresponsive NMIBC, Atezolizumab	SWOG	07FEB2017:00:00:00	14	41	148	4.2	May-2020

SWOG OPEN AND TEMPORARILY CLOSED STUDIES

Comm.	Phase	Study	Stat Center	Open Date	Months Open	Total Regs	Accrual Goal	Monthly Accrual Rate	Date of Expected Closure or Temporary Closure
	II-III	NRGGU002 Pros, RT + ADT After RP +/- Adj Docetaxel	NRG	30DEC2016:00:00:00		1		0.0	
	III	A031102 GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE)	ALLIANCE	01JUL2015:00:00:00		3		0.2	
		EA8143 RCC, HR, Surg +/- Nivolumab (PROSPER)	ECOG-ACR	02FEB2017:00:00:00		11		1.3	
		R0924 Pros, NADT+WPRT vs. NADT+P&SV RT	NRG	07JUL2011:00:00:00		72		2.7	
		S1602 Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG	SWOG	07FEB2017:00:00:00	14	92	969	8.2	Mar-2027
LEUK	I	S1312 ALL, CD22+, REL/REF, Inotuzumab+CVP	SWOG	01APR2014:00:00:00	48	38	38	0.2	Apr-2018
	I-II	S1318 ALL, Age 65+, Ph±, Blinatumomab	SWOG	12JAN2015:00:00:00		47	44		Sep-2017 Temp Close
	II-III	S1612 AML/MDS, Age 60+, Aza/Novel Therapeutics	SWOG	22DEC2017:00:00:00	4	13	1670	3.1	> 15 Yrs
	III	E1910 BCR-ABL-neg, B ALL, Blinatumomab	ECOG-ACRIN	23DEC2013:00:00:00		80		2.3	
		E2906 AML, Age 60+, Clo vs Dauno+Cy	ECOG-ACRIN	24FEB2011:00:00:00		75		0.0	
	OTHER	NHLBIMDS LEUK, National MDS Study	ECOG-ACRIN	05APR2016:00:00:00		10		0.8	
LUNG	II	S1400F Non-Match: MEDI4736 + Tremelimumab	SWOG	02OCT2017:00:00:00	6	17	132	2.8	Aug-2021
		S1400G HRRD: Talazoparib (BMN 673)	SWOG	07FEB2017:00:00:00	14	45	60	2.5	Sep-2018
		S1400K c-Met: ABBV-399 (Process II)	SWOG	05FEB2018:00:00:00	2	8	44		
	II-III	NRGCC003 SCLC, PCI or HA-PCI	NRG	07DEC2015:00:00:00		4		0.0	
	III	A081105 ALCHEMIST1, EGFR mut, Erlotinib	ALLIANCE	02JAN2014:00:00:00		38		1.7	
		C30610 SCLC, Thoracic RT	ALLIANCE	21MAR2008:00:00:00		55		0.5	
		E4512 ALCHEMIST2, ALK mut, Crizotinib	ECOG-ACR	18AUG2014:00:00:00		7		0.2	
		EA5142 ALCHEMIST3, Non-match, Nivolumab	ECOG-ACRIN	16MAY2016:00:00:00		43		3.2	
	OTHER	A151216 ALCHEMIST0 - screening	ALLIANCE	06FEB2014:00:00:00		493		17.8	
		S1400 SCCA,Adv, Biomarker Master	SWOG	15JUN2014:00:00:00	46	1606		33.8	
	PILOT	S1619 Meso,Stg I-III, Nadj chemo/Atezmb->Atezmb+SOC	SWOG	03NOV2017:00:00:00	5	0	28	0.0	Mar-2031
LYMPH	II	S1608 Rel/Ref FL, TGR-1202/Lenalidomide/CHOP + Ob	SWOG	10AUG2017:00:00:00	8	4	150	0.7	> 15 Yrs
	III	A051301 ABC DLBCL, Auto HCT and Ibrutinib/Placebo	ALLIANCE	15JUL2016:00:00:00		6		0.5	
		EA4151 Lymph, AHCT +/-Ritux, MRD Neg	ECOG-ACRIN	29AUG2017:00:00:00		1		0.2	
MELAN	II	S1320 Adv, BRAF mut, Inter v Contin	SWOG	22JUL2014:00:00:00	45	213	280	6.2	Feb-2019
		S1512 Melan, Adv, Desmoplastic, MK-3475 (pembro)	SWOG	20OCT2016:00:00:00	18	7	77	0.7	Dec-2026
		S1607 MELAN, Adv, T-VEC, MK-3475	SWOG	02OCT2017:00:00:00	6	0	64	0.0	> 15 Yrs
		S1616 MELAN, Adv, Ipilimumab ± Nivolumab	SWOG	17JUL2017:00:00:00	9	8	94	1.2	May-2024
	II-III	EA6141 Melan, Avd, Nivolumab+Ipi ± Sargmostim	ECOG-ACRIN	01MAR2016:00:00:00		36		0.0	
	III	EA6134 Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T	ECOG-ACR	15DEC2015:00:00:00		26		0.7	
MMYEL	I-II	S1211 MM,High Risk, RVD+/-ELO	SWOG	27OCT2012:00:00:00		142	110		Jun-2016 Temp Close
	II	S1702 AL Amyloidosis, Relapsed, Isatuximab	SWOG	08MAR2018:00:00:00	1	0	39		
	III	E1A11 MM, frontline, BLD vs CLD	ECOG-ACRIN	22NOV2013:00:00:00		199		9.3	
OTHER	I-II	A091304 Adv Sarc, MLN0128 v Pazopanib, Phi/II	ALLIANCE	26JAN2015:00:00:00		15		1.5	

26-APR-2018 6:10
SWOG OPEN AND TEMPORARILY CLOSED STUDIES

Comm.	Phase	Study	Stat Center	Open Date	Months Open	Total Regs	Accrual Goal	Monthly Accrual Rate	Date of Expected Closure or Temporary Closure
	II	A091202 Sarc, Efatutazone vs Placebo, Unresect ,Lipo	ALLIANCE	02SEP2014:00:00:00		2		0.0	
		A091305 HN, Adv, Thyroid PPAR agonist + Chemo	ALLIANCE	01SEP2014:00:00:00		2		0.0	
		A091401 Sarc,	ALLIANCE	18JUN2015:00:00:00		7		0.3	
		A091404 HN, AR+, Enzalutamide	ALLIANCE	25SEP2015:00:00:00		8		0.3	
		EA3132 HN SCC, Stg III-IV , Adj RT +/- Cisp	ECOG-ACRIN	29MAR2016:00:00:00		5		0.2	
		NRGBN001 HN, novel vs. std chemoradiation + chemo	NRG	28AUG2015:00:00:00		1		0.0	
	II-III	G0281 Ovar, Recur/prog LG, IC chemo vs trametinib	NRG	27FEB2014:00:00:00		1		0.0	
		G0286B Adv Endometrial, Metformin/Chemo	NRG			1			
		NRGGY005 OVAR, Cedir vs Olaparib vs C+O vs Std of Care	NRG	06FEB2016:00:00:00		3		0.0	
		NRGHN001 Nasopharyngeal , Individual Tx EBV	NRG	21APR2014:00:00:00		4		0.2	
		R1216 HN, Adv, Cis vs Dtx vs Dtx+Cetux	NRG	18MAR2013:00:00:00		3		0.0	
	III	G0263 Cerv, Stg I/IIA, adjv RT vs chemoRT	NRG	12APR2010:00:00:00		1		0.0	
		N0577 BRN, Glio, Tem vs Tem+RT vs RT+PVC	ALLIANCE			6			
		NRGGY011 ENDO, SURG WINDOW, MPA VS MPA+ENTINOSTATIN	NRG	12APR2010:00:00:00		2		0.3	
		R0724 Cervical, Chem+RT +/- Adj. Chemo	NRG	15JAN2014:00:00:00		1		0.0	
		R0920 HN, Adv, Postop IMRT ± Cetuximab	NRG	24DEC2013:00:00:00		11		0.0	
	OTHER	EAQ152 Communication & education in tumor profiling	ECOG-ACR	26SEP2016:00:00:00		11		0.0	
PREV	III	A211102 Breast, Atypia via RPFNA, Metformin v Placebo	ALLIANCE	01FEB2015:00:00:00		3		0.0	
		S0820 PACES: ColrecStg0-3 Blind DFMO/Sulindac	SWOG	01MAR2013:00:00:00	61	192	480	4.7	May-2023
SURV	III	E1Q11 EROS: Reproductive Health in Cancer Survivors	ECOG-ACR	30SEP2015:00:00:00		10		0.5	
		S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol	SWOG	15SEP2017:00:00:00	7	6	817	1.0	> 15 Yrs
	OTHER	EA9131 Leuk, Strategy to decrease early APL deaths	ECOG-ACR	16AUG2017:00:00:00		8		1.0	
		S1316 Compar. Effectiv. Trial for MBO	SWOG	09MAR2015:00:00:00		155	200		Apr-2018 Temp Close
SXQOL	III	A221101 Glioma, Nuvigil/Placebo Fatigue	ALLIANCE	03JUN2013:00:00:00		20		0.5	
		NRGGU003 Pros, Post-Prostatectomy HYPOR vs COPORT	NRG	28JUL2017:00:00:00		1		0.2	

Accrual goals assume studies are not terminated early as a result of interim analysis.
 Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.
 Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.
 Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.

OPEN AND TEMPORARILY CLOSED STUDIES: BY STUDY TYPE, COMMITTEE, INTERGROUP, SWOG/OTHER STAT CENTER

Phase	Comm.	Int grp	Stat Center	Study	NCIPROTO	CA Cntrl Study	Temp Close
OTHER	BREAST	Y	ECOG-ACRIN	E1Z11 Brst,Genetic Predictors of AIMSS	E1Z11	Y	
		Y	ALLIANCE	A221405 Breast, ET interruption, Pregnancy Outcomes	A221405	Y	
	CCD	N		S1417CD Colorectal, Cost Cohort Study		Y	
	ERLYTX	Y	ECOG-ACR	EAY131 MATCH	EAY131	N	
	LEUK	Y	ECOG-ACRIN	NHLBIMDS LEUK, National MDS Study	NHLBI-MDS	Y	
	LUNG	Y	SWOG	S1400 SCCA,Adv, Biomarker Master	S1400	N	
		Y	ALLIANCE	A151216 ALCHEMIST0 - screening	A151216	N	
	OTHER	Y	ECOG-ACR	EAQ152 Communication & education in tumor profiling	EAQ152	Y	
	SURV	Y	SWOG	S1316 Compar. Effectiv. Trial for MBO	S1316	Y	Y
		Y	ECOG-ACR	EA9131 Leuk, Strategy to decrease early APL deaths	EA9131	Y	
I	LEUK	N		S1312 ALL, CD22+, REL/REF, Inotuzumab+CVP		N	
I-II	LEUK	Y	SWOG	S1318 ALL, Age 65+, Ph±, Blinatumomab	S1318	N	Y
	MMYEL	Y	SWOG	S1211 MM,High Risk, RVD+/-ELO	S1211	N	Y
	OTHER	Y	ALLIANCE	A091304 Adv Sarc, MLN0128 v Pazopanib, Phi/II	A091304	N	
II	BREAST	Y	SWOG	S1416 Brst, TNBC/BRCA, Cis+/- ABT-888	S1416	N	
	ERLYTX	Y	SWOG	S1609 Rare Tumor, Comb Nivo/Ipi	S1609	N	
		Y	ALLIANCE	A071401 Prog Meningiomas,SMO/AKT/NF2 Inhib	A071401	N	
	GI	Y	SWOG	S1613 mCRC, Adv/Met, TP vs CETIRI	S1613	N	
		Y	ECOG-ACRIN	EA2142 GI NEC, Adv G3, EP vs TMZ + CAP	EA2142	N	
		Y	NRG	NRGGI002 Rectal, Ph II, Sensitization using TNT	NRG-GI002	N	
		Y	ALLIANCE	A021501 Adeno Panc,Borderline Resect,Chemo vs ChemoRT	A021501	N	
	GU	Y	SWOG	S1500 pRCC,Adv, Sunitinib vs MET inhib	S1500	N	
		Y	SWOG	S1605 Blad, BCG-Unresponsive NMIBC, Atezolizumab	S1605	N	
	LUNG	Y	SWOG	S1400G HRRD: Talazoparib (BMN 673)	S1400G	N	
		Y	SWOG	S1400K c-Met: ABBV-399 (Process II)	S1400K	N	
		Y	SWOG	S1400F Non-Match: MEDI4736 + Tremelimumab	S1400F	N	
	LYMPH	Y	SWOG	S1608 Rel/Ref FL, TGR-1202/Lenalidomide/CHOP + Ob	S1608	N	
	MELAN	Y	SWOG	S1320 Adv, BRAF mut, Inter v Contin	S1320	N	
		Y	SWOG	S1607 MELAN, Adv, T-VEC, MK-3475	S1607	N	
		Y	SWOG	S1616 MELAN, Adv, Ipilimumab ± Nivolumab	S1616	N	
		Y	SWOG	S1512 Melan, Adv, Desmoplastic, MK-3475 (pembro)	S1512	N	
	MMYEL	Y	SWOG	S1702 AL Amyloidosis, Relapsed, Isatuximab	S1702	N	
	OTHER	Y	NRG	NRGBN001 HN, novel vs. std chemoradiation + chemo	NRG-BN001	N	
		Y	ALLIANCE	A091202 Sarc, Efatutazone vs Placebo, Unresect ,Lipo	A091202	N	
		Y	ALLIANCE	A091401 Sarc,	A091401	N	
		Y	ALLIANCE	A091305 HN, Adv, Thyroid PPAR agonist + Chemo	A091305	N	
		Y	ALLIANCE	A091404 HN, AR+, Enzalutamide	A091404	N	

OPEN AND TEMPORARILY CLOSED STUDIES: BY STUDY TYPE, COMMITTEE, INTERGROUP, SWOG/OTHER STAT CENTER

Phase	Comm.	Int grp	Stat Center	Study	NCIPROTO	CA Cntrl Study	Temp Close
		Y	ECOG-ACRIN	EA3132 HN SCC, Stg III-IV , Adj RT +/- Cisp	EA3132	N	
PILOT	LUNG	Y	SWOG	S1619 Meso,Stg I-III, Nadj chemo/Atezmb->Atezmb+SOC	S1619	N	
II-III	BREAST	Y	NRG	NRGBR002 Brst, OMBC, II-III, SoC +/- SBRT and/or SA	NRG-BR002	N	
	ERLYTX	Y	ALLIANCE	A071102 GBM, adj TMZ +/- Veliparib	A071102	N	
		Y	COG	ARST1321 NonRhabdo STS,Pazopanib (PAZNTIS)	ARST1321	N	
	GI	Y	ALLIANCE	N1048 Rectal,LocalAdv,ChemoRT+/-FOLFOX	N1048	Y	
	GU	Y	NRG	NRGGU002 Pros, RT + ADT After RP +/- Adj Docetaxel	NRG-GU002	N	
	LEUK	Y	SWOG	S1612 AML/MDS, Age 60+, Aza/Novel Therapeutics	S1612	N	
	LUNG	Y	NRG	NRGCC003 SCLC, PCI or HA-PCI	NRG-CC003	Y	
	MELAN	Y	ECOG-ACRIN	EA6141 Melan, Avd, Nivolumab+Ipi ± Sargmostim	EA6141	N	
	OTHER	Y	NRG	NRGGY005 OVAR, Cedir vs Olaparib vs C+O vs Std of Care	NRG-GY005	Y	
		Y	NRG	G0286B Adv Endometrial,Metformin/Chemo	GOG-0286B	Y	
		Y	NRG	R1216 HN, Adv,Cis vs Dtx vs Dtx+Cetux	RTOG-1216	Y	
		Y	NRG	NRGHN001 Nasopharyngeal , Individual Tx EBV	NRG-HN001	Y	
		Y	NRG	G0281 Ovar, Recur/prog LG, IC chemo vs trametinib	GOG-0281	Y	
III	BREAST	N		S1222 Brst,Fulv. +/- Ever. +/- Anastr.		N	Y
		Y	SWOG	S1207 Brst,Adj,Endocrine+/-Everolimus	S1207	Y	
		Y	SWOG	S1418 Breast, Adj, TNBC, MK-3475 (Pembrolizumab)	S1418	Y	
		Y	ALLIANCE	A011202 Breast, Nodal XRT +/- ALND	A011202		
		Y	ALLIANCE	A011106 Breast, Neoadj, ALTERNATE study	A011106	N	
		Y	NRG	B51 Breast, Regional Nodal XRT	NSABP-B-51	Y	
		Y	ALLIANCE	A011401 Breast, adj, Stage II/III HER2-, weight loss	A011401	Y	
		Y	NRG	NRGBR003 Brst,Adj,TNBC,AC -> WP +/- Carbo	NRG-BR003	N	
		Y	ECOG-ACR	E2112 Brst,Adv,Exemestane+/-Entinostat	E2112	Y	
		Y	ALLIANCE	A011502 Brst, Adj, Nodal+&HER2-, Aspirin vs. Placebo	A011502	Y	
		Y	ECOG-ACRIN	EA1151 Brst, Tomosynthesis Mammographic Screening	EA1151	N	
		Y	NRG	B55 Brst, Adj Olaparib for BRCA,TNBC	NSABP-B-55	Y	
	CCD	Y	SWOG	S1415CD TrACER CSF Standing Order Intervention for FN	S1415CD	Y	
		Y	ALLIANCE	A011104 Preoperative Breast MRI	A011104	Y	
		Y	Alliance	A191402C PROS, Testing Decision Aids for Minority Men	A191402CD	Y	
	GI	Y	NRG	R0848 Panc, Adj, Erlotinib v ChemoRT	RTOG-0848	Y	
		Y	ALLIANCE	A021502 Colon, Stg III, Chemo +/- Atezol, ATOMIC	A021502	Y	
		Y	NRG	NRGGI004 Colorectal, Stg IV, dMMR Immuno-Therapy	NRG-GI004	N	
	GU	Y	SWOG	S1602 Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG	S1602	Y	
		Y	NRG	R0924 Pros, NADT+WPRT vs. NADT+P&SV RT	RTOG-0924	Y	
		Y	ECOG-ACR	EA8143 RCC, HR, Surg +/- Nivolumab (PROSPER)	EA8143	Y	
		Y	ALLIANCE	A031102 GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE)	A031102	Y	

OPEN AND TEMPORARILY CLOSED STUDIES: BY STUDY TYPE, COMMITTEE, INTERGROUP, SWOG/OTHER STAT CENTER

Phase	Comm.	Int grp	Stat Center	Study	NCIPROTO	CA	
						Study	Temp Close
LEUK	Y	ECOG-ACRIN	E2906 AML, Age 60+, Clo vs Dauno+Cy	E2906	Y		
	Y	ECOG-ACRIN	E1910 BCR-ABL-neg, B ALL, Blinatumomab	E1910	N		
LUNG	Y	ALLIANCE	C30610 SCLC, Thoracic RT	CALGB-30610	Y		
	Y	ALLIANCE	A081105 ALCHEMIST1, EGFR mut, Erlotinib	A081105	N		
	Y	ECOG-ACRIN	EA5142 ALCHEMIST3, Non-match, Nivolumab	EA5142	N		
	Y	ECOG-ACR	E4512 ALCHEMIST2, ALK mut, Crizotinib	E4512	N		
LYMPH	Y	ECOG-ACRIN	EA4151 Lymph, AHCT +/-Ritux, MRD Neg	EA4151	Y		
	Y	ALLIANCE	A051301 ABC DLBCL, Auto HCT and Ibrutinib/Placebo	A051301	N		
MELAN	Y	ECOG-ACR	EA6134 Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T	EA6134	Y		
MMYEL	Y	ECOG-ACRIN	E1A11 MM, frontline, BLD vs CLD	E1A11	Y		
OTHER	Y	NRG	R0920 HN, Adv, Postop IMRT ± Cetuximab	RTOG-0920	Y		
	Y	ALLIANCE	N0577 BRN, Glio,Tem vs Tem+RT vsRT+PVC	N0577	N		
	Y	NRG	G0263 Cerv, Stg I/IIA, adjv RT vs chemoRT	GOG-0263	Y		
	Y	NRG	NRGGY011 ENDO, SURG WINDOW, MPA VS MPA+ENTINOSTATNRG-GY011	NRG-GY011	N		
	Y	NRG	R0724 Cervical, Chem+RT +/- Adj. Chemo	RTOG-0724	Y		
PREV	Y	SWOG	S0820 PACES: ColrecStg0-3 Blind DFMO/Sulindac	S0820	Y		
	Y	ALLIANCE	A211102 Breast, Atypia via RPFNA, Metformin v Placebo	A211102	Y		
SURV	Y	SWOG	S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol	S1501	Y		
	Y	ECOG-ACR	E1Q11 EROS: Reproductive Health in Cancer Survivors	E1Q11	Y		
SXQOL	Y	ALLIANCE	A221101 Glioma, Nuvigil/Placebo Fatigue	A221101	Y		
	Y	NRG	NRGGU003 Pros, Post-Prostatectomy HYPOR vs COPORT	NRG-GU003	Y		